2 results
Approved WMOPending
The primary objective is to investigate the effect of bepranemab (45mg/kg and 90mg/kg Q4W) vs placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), a scale used to quantify the severity of symptoms of dementia, as the change from…
Approved WMORecruiting
To study the safety and efficacy of mitapivat in the treatment of adult subjects with sickle cell disease.